AI Summary

A securities fraud class action lawsuit has been filed against uniQure N.V. following a decline in the company's stock value. This development is attributed to a delay in FDA approval for one of the company's products. The lawsuit claims that uniQure N.V. failed to disclose information about the potential delay in FDA approval, which led to a significant decline in the company's stock value. As a result, investors may be eligible to participate in the class action lawsuit. Investors who purchased uniQure N.V. securities between certain dates may be able to recover their losses through the lawsuit. Those interested in learning more about the class action lawsuit can contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC.

AI summaries can be wrong sometimes—always verify important details using the source article.